AK-PENTOLATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AK-PENTOLATE (AK-PENTOLATE).
Antimuscarinic and anticholinergic agent that blocks muscarinic acetylcholine receptors, producing mydriasis and cycloplegia.
| Metabolism | Primarily hepatic via ester hydrolysis; metabolites are excreted renally. |
| Excretion | Renal 85% as unchanged drug; fecal 10% as metabolites; biliary 5%. |
| Half-life | Terminal elimination half-life 1.5-2 hours in adults; prolonged in neonates (up to 12 hours) due to immature hepatic and renal function. |
| Protein binding | 50-70% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.2-0.4 L/kg; distributes into total body water; higher Vd in pediatric patients. |
| Bioavailability | Topical ophthalmic: approximately 10% systemic absorption via nasolacrimal duct; oral: 25-30% due to first-pass metabolism. |
| Onset of Action | Topical ophthalmic: 5-10 minutes for mydriasis; 30 minutes for cycloplegia. |
| Duration of Action | Mydriasis 6-12 hours; cycloplegia 12-24 hours. Complete recovery may take up to 48 hours. |
| Molecular Weight | 291.39 Da |
1 to 2 drops of 1% solution in the eye(s) every 5 to 10 minutes for 1 to 2 doses prior to examination.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No adjustment required; ophthalmic use has negligible systemic absorption. |
| Liver impairment | No adjustment required; ophthalmic use has negligible systemic absorption. |
| Pediatric use | Children: 1 drop of 0.5% or 1% solution 40 to 50 minutes before examination; may repeat in 20 to 30 minutes for adequate cycloplegia. |
| Geriatric use | Use lowest effective dose; caution for increased intraocular pressure risk. |
| 1st trimester | There are no adequate and well-controlled studies in pregnant women. AK-PENTOLATE (cyclopentolate) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal reproduction studies have not been conducted. |
| 2nd trimester | Same as T1. |
| 3rd trimester | Same as T1. However, anticholinergic effects may theoretically cause neonatal adverse effects if used near term. |
Clinical note
Comprehensive clinical and safety monograph for AK-PENTOLATE (AK-PENTOLATE).
| Placental transfer | Cyclopentolate is a small molecule and likely crosses the placenta, but no specific data on placental transfer are available. |
| Breastfeeding | Cyclopentolate is excreted in breast milk in small amounts. After ophthalmic administration, systemic absorption is low. However, because of the potential for anticholinergic effects in the infant, caution should be exercised. Consider using the lowest effective dose and avoiding prolonged use. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to cyclopentolate or any component of the formulationNarrow-angle glaucomaUntreated angle-closure glaucoma
| Precautions | Elevated intraocular pressure in patients with narrow-angle glaucoma, May cause CNS effects (e.g., somnolence, confusion) especially in children, Photosensitivity due to mydriasis |
| Food/Dietary | No specific food interactions. However, because the drug may cause anticholinergic effects like dry mouth, patients should avoid excessive caffeine or alcohol which can exacerbate these effects. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 (Limited Data - Probably Compatible) |
| Teratogenic Risk | Anticholinergic effects may cause fetal tachycardia; no adequate studies in pregnant women. Avoid in first trimester if possible. Fetal risk cannot be excluded. |
| Fetal Monitoring | Monitor maternal heart rate and blood pressure; fetal heart rate monitoring recommended with prolonged use or high doses. |
| Fertility Effects | No known adverse effects on fertility based on available data. |
| AK-PENTOLATE (cyclopentolate) is an anticholinergic ophthalmic agent used for mydriasis and cycloplegia. It has a faster onset and shorter duration than atropine but may cause systemic anticholinergic effects, especially in children and elderly. Use 1 drop of 0.5% or 1% solution; repeat in 5 minutes if needed. Avoid in patients with narrow-angle glaucoma. Monitor for central nervous system toxicity in infants. |
| Patient Advice | Wash hands before and after eye drop administration. · Avoid touching the dropper tip to prevent contamination. · Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after instillation to reduce systemic absorption. · May cause blurred vision and photophobia; wear sunglasses and avoid driving until vision clears. · Discontinue use and contact doctor if eye pain, redness, or vision changes occur. · Do not use while wearing contact lenses; remove before instillation and wait 15 minutes before reinserting. |